Pepe Lee Chang is an associate professor in the Department of Management at The University of Texas at San Antonio. She joined the UTSA faculty in 2007 after completing her doctorate in philosophy. Her Ph.D. is from The University of Utah, Department of Philosophy. Her B.S. degree is also from the University of Utah in business.
Dr. Chang oversees and instructs the college's MBA ethics curriculum. She also teaches business ethics for the Honors College. Her current research involves the cross section of business ethics and medical ethics in the pharmaceutical industry. Other research interests include the practical application of the philosophy of Bernard Williams, corporate social responsibility, leadership, moral philosophy and Nietzsche.
- Business Ethics/Social Issues in Management
- Moral Philosophy/Ethics
- Stakeholder Theory and the Commodification of Healthcare
- Pharmaceutical Industry
- Ethics and Globalization (MBA/Graduate)
- Legal, Ethical and Social Issues in Health Care Management (MBA/Graduate)
- Leadership and Ethics (MBA/Graduate)
- International Business Ethics (MBA/Graduate)
- Social and Ethical Issues in Business (Undergraduate)
- Business Ethics (Undergraduate)
- Bioethics (Undergraduate)
"The Abandoned Stakeholders: Pharmaceutical Companies and Research Participants," Journal of Business Ethics, 2016.
“You Might Not Have Access,” Theoretical and Applied Ethics, Vol. 2, No. 1, Summer 2013, pp. 93-102.
“Pharmaceutical Companies: The Perfect Scapegoat for Everything,” The American Journal of Bioethics, Vol. 13, No. 5, May 2013, pp. 30-32.
“The Moral Asymmetry of Gametic Contributions,” with Diana Buccafurni, The American Journal of Bioethics, Vol. 13, No. 5, May 2013, pp. 56-58.
“Is Invading the Sacred for the Sake of Justice Justified?” with Diana Buccafurni, The American Journal of Bioethics, Vol. 1, No. 3, 2010, pp. 48-50.
“Does Prenatal Diagnosis Morally Require Provision of Selective Abortion?” with Diana Buccafurni, The American Journal of Bioethics, Vol. 9, No. 8, 2009, pp. 65-67.
“Pharmaceutical Companies and Their Obligations to Developing Countries: Psychopaths or Scapegoats?” Innovation and the Pharmaceutical Industry: Critical Reflections on the Virtues of Profit, M&M Scrivener Press, 2008, pp. 46-66.
“A Typology of Universities’ Ethical Infractions: Classifying the Types and Levels of Seriousness of Ethical Lapses in University Settings,” with Patricia Kelley, Journal of Higher Education, Vol. 78, No. 4, 2007, pp. 402-429.
“Who’s in the Business of Saving Lives?” Journal of Medicine and Philosophy, Vol. 31, No. 5, 2006, pp. 465-482.